University of South Alabama   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Mobile AL United States (1963)

Organization Overview

First Clinical Trial
2001
NCT00153127
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Jon Simmons | Mobile Infirmary Hospital, Mobile, AL | University of South Alabama | University Of South Alabama, Children's & Women's Hospital | University of South Alabama College of Medicine | University of South Alabama Department of Neurology | University of South Alabama Medical Center | University of South Alabama Medical Center, Mobile, AL | University of South Alabama Neurology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Blindness (Phase 4)

Breast Neoplasms (Phase 4)

Bronchopulmonary Dysplasia (Phase 2)

Burns (Phase 2)

Communicable Diseases (Phase 2)

Constipation (Phase 4)

Coronavirus Infections (Phase 3)

Ductus Arteriosus, Patent (Phase 2)

Egg Hypersensitivity (Phase 2)

Headache (Phase 2)

Infections (Phase 2)

Inflammatory Bowel Diseases (Phase 4)

Migraine Disorders (Phase 2)

Premature Birth (Phase 4)

Respiratory Insufficiency (Phase 2)

Retinal Detachment (Phase 4)

Retinal Diseases (Phase 4)

Retinopathy of Prematurity (Phase 4)

Seizures (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Surgical Wound (Phase 2)

Surgical Wound Infection (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Virus Diseases (Phase 3)

Wound Infection (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 42